Impact of Human Papillomavirus Vaccination on Male Disease: A Systematic Review
Vaccines · 09.06.2023 · 11 (6) · 1083
DOI: 10.3390/vaccines11061083 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 09.06.2023. Verfasst von Catarina Rosado und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Microbiology, Department of Pathology, Faculty of Medicine, University of Porto, 4200-039 Porto, Portugal. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon Europe programme and Norte 2020, Horizon Europe program and Norte 2020.
Abstract (Originalsprache)
Human papillomavirus (HPV)-related diseases are highly prevalent in men worldwide, comprising external anogenital condyloma, anal intraepithelial neoplasia (AIN), penile intraepithelial neoplasia (PIN), and anogenital and oropharyngeal cancers. There is exceptionally low vaccine coverage in the male population. Only 4% of men were fully vaccinated, worldwide, as of 2019. The aim of this review is to assess the impact of HPV vaccination on male disease. Three databases (MEDLINE, Web of Science, Scopus) and Clinical Trials.gov were searched. We included thirteen studies, eight randomized controlled trials (RCTs), and five cohorts, comprising a total of 14,239 participants. Regarding anal disease, seven studies reported HPV vaccine efficacy ranging from 91.1% to 93.1% against AIN1, and ranging from 89.6% to 91.7% against AIN2|3 and anal cancer. Five studies showed an efficacy against genital condyloma of 89.9% in HPV-naïve males, varying between 66.7% and 67.2% in intention-to-treat populations. Studies reporting no efficacy have included older participants. These results support vaccination of young men previously infected, beyond HPV-naïve males. The evidence quality was moderate to low for most outcomes, namely genital diseases. RCTs are needed to assess the efficacy of HPV vaccination on male oropharyngeal cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Microbiology, Department of Pathology, Faculty of Medicine, University of Porto, 4200-039 Porto, Portugal.
- CINTESIS@RISE, Center of Health Technology and Services Research/Rede de Investigação em Saúde, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal.
- Department of Dermatology and Venereology, Centro Hospitalar Universitário São João, 4200-319 Porto, Portugal.
ORCID-Profile: Ângela Rita Fernandes, Carmen Lisboa
Förderung
- Horizon Europe programme and Norte 2020
- Horizon Europe program and Norte 2020
Zitieren
APA
Rosado, C., Fernandes, Â. R., Rodrigues, A. G., & Lisboa, C. (2023). Impact of Human Papillomavirus Vaccination on Male Disease: A Systematic Review. Vaccines, 11(6), 1083. https://doi.org/10.3390/vaccines11061083
Vancouver
Rosado C, Fernandes ÂR, Rodrigues AG, Lisboa C. Impact of Human Papillomavirus Vaccination on Male Disease: A Systematic Review. Vaccines. 2023;11(6):1083. doi:10.3390/vaccines11061083
BibTeX
@article{Rosado2023,
author = {Rosado, Catarina and Fernandes, Ângela Rita and Rodrigues, Acácio Gonçalves and Lisboa, Carmen},
title = {Impact of Human Papillomavirus Vaccination on Male Disease: A Systematic Review},
journal = {Vaccines},
year = {2023},
volume = {11},
number = {6},
pages = {1083},
doi = {10.3390/vaccines11061083}
}
EUVIMED